Cargando…

Cell therapies for Duchenne muscular dystrophy: some ethical issues for personalised medicines

Detalles Bibliográficos
Autor principal:	McCormack, Pauline
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958424/ http://dx.doi.org/10.1186/1750-1172-5-S1-P8

Ejemplares similares

Serial assessment of myocardial T2 in Duchenne muscular dystrophy
por: Wansapura, Janaka, et al.
Publicado: (2011)

Elevated myocardial extracellular volume fraction in Duchenne muscular dystrophy
por: Starc, James, et al.
Publicado: (2016)

Effect of pulmonary function on right heart function in Duchenne muscular dystrophy patients
por: Subramanian, Sharath, et al.
Publicado: (2015)

T1 mapping is abnormal before decline in EF in patients with Becker and Duchenne muscular dystrophy
por: Soslow, Jonathan H, et al.
Publicado: (2013)

Progression of myocardial fibrosis by magnetic resonance imaging in patients with Duchenne and Becker muscular dystrophy
por: Silva, Marly C, et al.
Publicado: (2013)

Myocardial T1 and T2 Mapping in Duchenne muscular dystrophy: characterization of late gadolinium Eenhancement
por: Soslow, Jonathan H, et al.
Publicado: (2016)

Left ventricular function by echocardiography correlates poorly with cardiac MRI measures in Duchenne muscular dystrophy
por: Soslow, Jonathan H, et al.
Publicado: (2014)

Precision Medicine and Exercise Therapy in Duchenne Muscular Dystrophy
por: Kostek, Matthew
Publicado: (2019)

Quantitative left ventricular rotational mechanics in Duchenne and Becker muscular dystrophy patients
por: Wang, Zhe, et al.
Publicado: (2015)

Presence of late gadolinium enhancement in Duchenne muscular dystrophy patients is associated with age and global ventricular function
por: Hor, Kan N, et al.
Publicado: (2012)

Left ventricular T2 distribution in Duchenne Muscular Dystrophy
por: Wansapura, Janaka, et al.
Publicado: (2009)

Gene Therapy for Duchenne Muscular Dystrophy
por: Elangkovan, Nertiyan, et al.
Publicado: (2021)

Cardiac therapies for Duchenne muscular dystrophy
por: Shah, Md Nur Ahad, et al.
Publicado: (2023)

P125 The effect of glucocorticoids on rate of lung function decline in Duchenne Muscular Dystrophy patients receiving Non-Invasive Ventilation
por: Treanor, D, et al.
Publicado: (2022)

The effect of free-breathing on left ventricular rotational mechanics in normal subjects and patients with duchenne muscular dystrophy
por: Reyhan, Meral, et al.
Publicado: (2015)

Symptomatic therapy of Duchenne Muscular Dystrophy (DMD)
por: Rüdel, Reinhardt
Publicado: (2012)

Vascular-targeted therapies for Duchenne muscular dystrophy
por: Ennen, James P, et al.
Publicado: (2013)

Duchenne Muscular Dystrophy: From Diagnosis to Therapy
por: Falzarano, Maria Sofia, et al.
Publicado: (2015)

From diagnosis to therapy in Duchenne muscular dystrophy
por: Babbs, Arran, et al.
Publicado: (2020)

Vascular therapy for Duchenne muscular dystrophy (DMD)
por: Thapa, Sangharsha, et al.
Publicado: (2023)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

Association between specific dystrophin gene mutations and myocardial fibrosis by cardiovascular magnetic resonance imaging in patients with Duchenne and Becker muscular dystrophy
por: Silva, Marly C, et al.
Publicado: (2014)

New Recommendation on Biological Materials Could Hamper Muscular Dystrophy Research
por: McCormack, Pauline, et al.
Publicado: (2016)

Differences in cardiac involvement between carriers of Duchenne and Becker muscular dystrophy - a cardiovascular magnetic resonance study
por: Florian, Anca R, et al.
Publicado: (2015)

Trends in steroid therapy for Duchenne muscular dystrophy in Japan
por: Takeuchi, Fumi, et al.
Publicado: (2016)

Genome Editing Gene Therapy for Duchenne Muscular Dystrophy
por: Hotta, Akitsu
Publicado: (2015)

Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy
por: Wilton-Clark, Harry, et al.
Publicado: (2023)

The role of fibrosis in Duchenne muscular dystrophy
por: KLINGLER, WERNER, et al.
Publicado: (2012)

Delay in Diagnosis of Duchenne Muscular Dystrophy
por: Rao, Vamshi K., et al.
Publicado: (2015)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Targeting angiogenesis in Duchenne muscular dystrophy
por: Podkalicka, Paulina, et al.
Publicado: (2019)

Regenerative biomarkers for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2019)

Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)

Nutritional Challenges in Duchenne Muscular Dystrophy
por: Salera, Simona, et al.
Publicado: (2017)

Lifetime Care of Duchenne Muscular Dystrophy
por: MacKintosh, Erin W., et al.
Publicado: (2020)

The Duchenne muscular dystrophy gene and cancer
por: Jones, Leanne, et al.
Publicado: (2020)

CRISPR Therapeutics for Duchenne Muscular Dystrophy
por: Erkut, Esra, et al.
Publicado: (2022)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m6stv6h9m833t1jnhic0s8uius